Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment of renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.
LAMPGEN ANALYSIS
Why it matters
The indication moves PD-1 inhibition into a postoperative renal cell carcinoma setting.
What research teams should watch
Reconcile resection and pathology reports and document recurrence risk, residual disease status and eligibility timing.
PRIMARY RECORDS